HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins. - Test2 - elhamkhani - TriplyDB

HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins.

HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins.

http://www.wikidata.org/entity/Q34480529

about

Drugging the undruggables: exploring the ubiquitin system for drug development Induced protein degradation: an emerging drug discovery paradigm.PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.Crystal Structure of the Cul2-Rbx1-EloBC-VHL Ubiquitin Ligase Complex.Selective chemical labeling of proteins.Targeted Protein Degradation by Small Molecules.Targeted protein knockdown using small molecule degraders.Targeted Protein Degradation: from Chemical Biology to Drug Discovery.Selective Targeting of Cells via Bispecific Molecules That Exploit Coexpression of Two Intracellular Proteins.Light-Up "Channel Dyes" for Haloalkane-Based Protein Labeling in Vitro and in Bacterial Cells.pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase.Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.A small cassette enables conditional gene inactivation by CRISPR/Cas9.Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.Protein degradation: DCAFinating splicing.Thioamide substitution to probe the hydroxyproline recognition of VHL ligands.Design, Synthesis, and Characterization of Brequinar Conjugates as Probes to Study DHODH Inhibition.Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands.Degradation of HaloTag-fused nuclear proteins using bestatin-HaloTag ligand hybrid molecules.Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase Next-Generation Drugs and Probes for Chromatin Biology: From Targeted Protein Degradation to Phase Separation

P2860

Q26752823-0808480C-0017-4E60-93C0-64DD331F9036 Q34545841-88015589-7A1F-4C74-8521-DFDBE64C152E Q37065079-F85A4F39-E99F-4A12-A197-93CFE371C7EB Q38673650-420F3909-D1A8-4C65-98AD-B4E10B6A9523 Q38759843-50CD341C-A63F-411A-A9C3-E4CF76F08487 Q38978952-F33D5FE8-E276-4668-9873-87E46BF9FE85 Q39367115-807CA936-0AEC-4622-954C-298B110C6076 Q39396984-C64A96EC-7489-4655-8C6C-45EEDC56EC91 Q41023966-4370FDC5-DF04-49EA-9A6D-D58BBDD825D4 Q41530151-CC1B30F5-B014-4ACA-B04C-74AF50E200DA Q42101565-391591A2-FBCB-4ABD-B31D-226F656F572C Q42217007-DBCA0233-E8D7-4064-9BCA-ABDC964A475D Q47121618-AF5041CD-3DBD-4288-998B-32E7D40EB20E Q47411643-7006FE78-A3E9-420B-8258-06F62257CE3E Q47411655-0BA31A56-890E-4D9D-B97C-CBA6D62F23BB Q51038219-812A82FB-A53A-4219-81B6-AA9A2D3E3A5D Q52323183-D25CCFEE-1D97-4116-938C-D6EDCB9B6868 Q52537222-6E93694F-BC38-4CE9-8427-BC186DF74137 Q52673134-0E06C6FD-54D9-41EF-B6A6-6199F31FE897 Q55043775-248A23D7-BD46-4B84-9C27-1B81C2208631 Q58738119-F451B19B-9313-440C-A01A-6589F95AC59F Q58756135-147FF1A6-5944-4CF0-901C-ABE15A2FE8EF Q58798742-EC9D5140-3D06-4D85-89A6-8E9B6C88A7CF

P2860

HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins.

http://www.wikidata.org/entity/Q34480529

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

HaloPROTACS: Use of Small Mole ...... on of HaloTag Fusion Proteins.

@ast

HaloPROTACS: Use of Small Mole ...... on of HaloTag Fusion Proteins.

@en

HaloPROTACS: Use of Small Mole ...... on of HaloTag Fusion Proteins.

@nl

type

label

HaloPROTACS: Use of Small Mole ...... on of HaloTag Fusion Proteins.

@ast

HaloPROTACS: Use of Small Mole ...... on of HaloTag Fusion Proteins.

@en

HaloPROTACS: Use of Small Mole ...... on of HaloTag Fusion Proteins.

@nl

prefLabel

HaloPROTACS: Use of Small Mole ...... on of HaloTag Fusion Proteins.

@ast

HaloPROTACS: Use of Small Mole ...... on of HaloTag Fusion Proteins.

@en

HaloPROTACS: Use of Small Mole ...... on of HaloTag Fusion Proteins.

@nl

P1433

Q34480529-EB86FB1C-46AD-4365-8DE7-F3AEA9336252

P1476

Q34480529-16C174CC-8E51-4027-AA79-CC92DCE77384

P2093

Q34480529-2F12AC68-72C7-4930-9FA2-67EC21194957

Q34480529-4E637CF9-2839-4D56-B20E-A157CC0CDFBD

Q34480529-4F0ACA81-E8E4-4119-A493-60AC5BBCBF28

Q34480529-57C9F9BF-844D-4540-A0D1-B7F9DA2E6088

Q34480529-A1F0194E-2397-4B9E-8ACD-FE6721C7D429

Q34480529-B51F8A90-EFF9-4DE9-8DC9-89CF4194E8BF

Q34480529-BB48DA37-3F6A-4D41-83C6-D8CB5D3E222F

Q34480529-DDB11DFF-04D2-491A-B898-E7FC1EEF17DF

Q34480529-F12E56DB-2C47-4067-956E-14D95EFF5D0E

P2860

Q34480529-04F0BD2E-B7C2-4EBD-B2E0-0775C81600C7

Q34480529-158EDAB3-A054-45F6-B1FF-E79BEE9F12D8

Q34480529-1603FA73-BAD3-4F00-9E84-4EE83A28ED1D

Q34480529-24A17A91-E918-4332-9876-0E7AC8E7903A

Q34480529-2A5D1D6E-434E-43F1-8FCF-FDA1070229CF

Q34480529-3884AFDF-D603-4551-B98B-76C3B1D89BAC

Q34480529-3A05F9B8-5452-4848-9BB0-18D2AA4019F9

Q34480529-4C855A08-EDE0-42B9-A69A-4BD77E8A4CD5

Q34480529-4EDFC21E-E114-4A88-A7BA-76CD0CE80E9F

Q34480529-505A071B-298B-4DC7-9ADB-2E8412CA6A33

P304

Q34480529-ED530F57-2891-4A53-94D6-53FD88D6D6F9

P31

Q34480529-60B2CB5C-97ED-4670-A646-C5A756E41A91

P356

Q34480529-6D38E7B9-C9E0-4D54-B7E3-F6A47C81655D

P433

Q34480529-723EE174-7367-4A97-941E-A333338C1F43

P478

Q34480529-2AB74CB3-CC05-4004-A1E7-218748262402

P577

Q34480529-BF0F847F-72D8-4DBF-960A-2D7671534300

P698

Q34480529-B810314D-4E29-4DD0-BE38-DC41C9D3126D

P932

Q34480529-2BED026E-D8DA-4FF2-BFD4-D0C88EDB0D9F

P356

ACSCHEMBIO.5B00442

P1433

ACS Chemical Biology

P1476

HaloPROTACS: Use of Small Mole ...... on of HaloTag Fusion Proteins.

@en

P2093

Afjal H Miah

http://www.w3.org/2001/XMLSchema#string

Craig M Crews

http://www.w3.org/2001/XMLSchema#string

Dennis L Buckley

http://www.w3.org/2001/XMLSchema#string

Ian E Smith

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Gustafson

http://www.w3.org/2001/XMLSchema#string

John D Harling

http://www.w3.org/2001/XMLSchema#string

John Hines

http://www.w3.org/2001/XMLSchema#string

Kanak Raina

http://www.w3.org/2001/XMLSchema#string

Nicole Darricarrere

http://www.w3.org/2001/XMLSchema#string

P2860

IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis

Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

Small-Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1α

Dissecting Fragment-Based Lead Discovery at the von Hippel-Lindau Protein:Hypoxia Inducible Factor 1α Protein-Protein Interface

Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction

Targeting RAS signalling pathways in cancer therapy

Development of target protein-selective degradation inducer for protein knockdown.

Protacs for treatment of cancer.

Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes.

P304

1831-1837

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/ACSCHEMBIO.5B00442

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26070106

http://www.w3.org/2001/XMLSchema#string

P932

4629848

http://www.w3.org/2001/XMLSchema#string